137 related articles for article (PubMed ID: 20083692)
1. Recent trends in systemic psoriasis treatment costs.
Beyer V; Wolverton SE
Arch Dermatol; 2010 Jan; 146(1):46-54. PubMed ID: 20083692
[TBL] [Abstract][Full Text] [Related]
2. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?
Balkrishnan R; Bhosle MJ; Fleischer AB; Feldman SR
J Dermatolog Treat; 2010 May; 21(3):178-84. PubMed ID: 19821787
[TBL] [Abstract][Full Text] [Related]
3. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
6. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
Gross DJ; Schondelmeyer SW; Raetzman SO
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
[TBL] [Abstract][Full Text] [Related]
7. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
D'Souza LS; Payette MJ
J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
[TBL] [Abstract][Full Text] [Related]
8. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
[TBL] [Abstract][Full Text] [Related]
9. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany.
Berger K; Ehlken B; Kugland B; Augustin M
J Dtsch Dermatol Ges; 2005 Jul; 3(7):511-8. PubMed ID: 15967010
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies.
Pearce DJ; Nelson AA; Fleischer AB; Balkrishnan R; Feldman SR
J Dermatolog Treat; 2006; 17(1):29-37. PubMed ID: 16467021
[TBL] [Abstract][Full Text] [Related]
11. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
12. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
Rosenberg ME; Rosenberg SP
JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
[TBL] [Abstract][Full Text] [Related]
13. Economic considerations in psoriasis management.
Radtke MA; Augustin M
Clin Dermatol; 2008; 26(5):424-31. PubMed ID: 18755360
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
[TBL] [Abstract][Full Text] [Related]
16. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis.
Bhosle MJ; Feldman SR; Camacho FT; Timothy Whitmire J; Nahata MC; Balkrishnan R
J Dermatolog Treat; 2006; 17(5):294-301. PubMed ID: 17092860
[TBL] [Abstract][Full Text] [Related]
18. Health care costs and mortality for Canadian urban and rural patients with diabetes: population-based trends from 1993-2001.
Pohar SL; Majumdar SR; Johnson JA
Clin Ther; 2007 Jun; 29(6 Pt 1):1316-24. PubMed ID: 18036393
[TBL] [Abstract][Full Text] [Related]
19. Social Security cost-of-living adjustments and the Consumer Price Index.
Burdick C; Fisher L
Soc Secur Bull; 2007; 67(3):73-88. PubMed ID: 18605219
[TBL] [Abstract][Full Text] [Related]
20. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
